Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Amarin Corporation’s cardiovascular study is nearing completion
March 1, 2018 Off

Amarin Corporation’s cardiovascular study is nearing completion

By Dino Mustafić

Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.

March 1, 2018 Off

Basilea Pharmaceutica names Kaul as its Management Committee’s Chief Development Officer

By Dino Mustafić

Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities…

Novartis and Pear Therapeutics work on prescription digital therapeutics for patients with schizophrenia and multiple sclerosis
March 1, 2018 Off

Novartis and Pear Therapeutics work on prescription digital therapeutics for patients with schizophrenia and multiple sclerosis

By Dino Mustafić

Novartis and Pear Therapeutics will develop new treatments for patients with schizophrenia and multiple sclerosis, with Pear’s prescription digital therapeutics…

Gelesis bags $30 million to prepare for regulatory approval of its weight loss capsules
March 1, 2018 Off

Gelesis bags $30 million to prepare for regulatory approval of its weight loss capsules

By Dino Mustafić

PureTech Health’s affiliate Gelesis has rasied $30 million to back bringing closer to shelves its pipeline of additinoal gastrointestinal disorders product candidates,…

EMA grants accelerated assessment for Shire’s Lanadelumab being evaluated for the prevention of attacks in Hereditary Angioedema patients aged 12 years and older
February 28, 2018 Off

EMA grants accelerated assessment for Shire’s Lanadelumab being evaluated for the prevention of attacks in Hereditary Angioedema patients aged 12 years and older

By Dino Mustafić

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for…

February 28, 2018 Off

Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A

By Dino Mustafić

Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…

FDA rejects Celgene’s NDA for multiple sclerosis treatment
February 28, 2018 Off

FDA rejects Celgene’s NDA for multiple sclerosis treatment

By Dino Mustafić

Celgene Corporation (NASDAQ:CELG) has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug…

AstraZeneca’s MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
February 28, 2018 Off

AstraZeneca’s MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics

By Dino Mustafić

AstraZeneca’s global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes…

Horizon Pharma submits supplemental New Drug Application for Ravicti oral liquid to expand age range to include newborns
February 28, 2018 Off

Horizon Pharma submits supplemental New Drug Application for Ravicti oral liquid to expand age range to include newborns

By Dino Mustafić

Horizon Pharma plc (NASDAQ:HZNP) has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA)…

Basilea gets closer to profitability with increased revenue driven by Cresemba and Zevtera sales. Aims US market with its oncology program
February 27, 2018 Off

Basilea gets closer to profitability with increased revenue driven by Cresemba and Zevtera sales. Aims US market with its oncology program

By Dino Mustafić

Basilea Pharmaceutica’s revenue in 2017 increased to CHF 101.5 million fromCHF 66.0 million in 2016, which represents an increase of…

Posts pagination

Previous 1 … 3,400 3,401 3,402 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine